American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Almost 90% of patients responded to infusions of the LCAR B38M, and the majority of complete responders became minimal residual disease–negative. Read More ›

GRIFFIN Study: Daratumumab Deepens Responses Over Time

ASH 2019 – Multiple Myeloma

Newly diagnosed patients receiving daratumumab/lenalidomide/dexamethasone achieved rapid and deep responses. Read More ›

Baseline PET/CT Findings Have Prognostic Value in Newly Diagnosed Multiple Myeloma

ASH 2019 – Multiple Myeloma

Positron emission tomography combined with computed tomography (PET/CT)/minimal residual disease–negativity concordance could be a predictive surrogate for patient outcomes. Read More ›

Daratumumab plus Standard of Care Improves Overall Survival in ALCYONE Trial

ASH 2019 – Multiple Myeloma

For the first time, overall survival benefit of adding daratumumab to standard of care in newly diagnosed, transplant-ineligible multiple myeloma patients is confirmed. Read More ›

Daratumumab Maintenance Deepens Responses, Survival in Multiple Myeloma

ASH 2019 – Multiple Myeloma

After induction with daratumumab and CyBorD, maintenance daratumumab improves depth of response and survival in newly diagnosed and relapsed multiple myeloma. Read More ›

American Society of Hematology (ASH)

Page 19 of 44